[Clinical and epidemiologic description of a severe outbreak of Salmonellosis in an urban nursery school]. / Descripción clínica y epidemiológica de un brote grave de salmonelosis en una escuela infantil urbana.

OBJECTIVE: We describe clinically and epidemiologically an outbreak of gastrointestinal infection by Salmonella enterica ser. (serotype) Enteritidis in an urban infant school, which led to high morbidity and significant social alarm. The immediate communication, as well as the adequate study of the outbreak, in both aspects, allowed identifying the pathogen and establishing control measures in a reasonable period of time. Controversial aspects such as the indication of antibiotherapy or the moment of closing the center are discussed. METHODS: We retrospectively collected clinical, analytical and epidemiological information and we reviewed the methodology of the outbreak study and its results. RESULTS: A total of 57 children (3-45 months), were affected and had microbiological confirmation. Diarrhea and fever were the main symptoms. 74% went to the hospital and 37% were admitted (mean stay 3.3 days). Factors associated with admission were: dehydration, significant elevation of acute phase reactants and coagulopathy. Twelve patients received parenteral cefotaxime. There were 2 complications: 1 bacteremia and 1 readmission. The initial suspicion of the origin of the outbreak was food, but the analysis of the control samples was negative. Five workers were positive (2 symptomatic). Epidemiologic Surveillance concluded that the probable origin of the outbreak was an asymptomatic carrier and improper diapers handling. The center was closed for 8 days. Cleaning and disinfection measures were carried out, as well as instruction on diaper changing, and the carriers were followed. CONCLUSIONS: Clustering in time and space of cases should be reported immediately for early control of the outbreak. Children may present severe forms of Salmonella gastroenteritis.

Variaciones en la incidencia de bronquiolitis tras la aparición del SARS-CoV-2 / Variations in the incidence of bronchiolitis after the onset of SARS-CoV-2

Introducción. Durante la temporada 2020-2021 se ha asistido a una disminución de la incidencia de hospitalizaciones por bronquiolitis. Los cambios en la evolución de la pandemia de SARS-CoV-2 y en la aplicación de medidas preventivas podrían relacionarse con un aumento de la incidencia de bronquiolitis grave durante la temporada 2021-2022. Objetivo. Determinar la incidencia de hospitalizaciones por bronquiolitis en un hospital terciario durante la temporada 2021-2022 y compararla con temporadas previas. Método. Estudio epidemiológico de tipo observacional, descriptivo y ambispectivo. A través de la base de datos de un hospital terciario, se compararon la incidencia, la etiología y los indicadores de gravedad de las hospitalizaciones por bronquiolitis. Se analizaron 3 cohortes en época epidémica: la temporada 2020-2021 y la 2021-2022 (prospectivas); y la temporada 2018-2019 (retrospectiva). También se analizó una cohorte prospectiva entre los meses de abril y octubre de 2021. Resultados. La incidencia acumulada de hospitalizaciones fue de 113,6/10.000 niños menores de 2 años en la temporada pre-covídica; de 3,6/10.000 en la temporada 2020-2021; y de 65,7/10.000 en la temporada 2021-2022. El porcentaje de ingresos en UCIP fue de 36,6%, 0 % y 30,8%, respectivamente. La incidencia acumulada de hospitalizaciones en el periodo no epidémico fue de 60,8/10.000, precisando ingreso en UCIP el 19%. El microorganismo más frecuente fue el virus respiratorio sincitial en todas las cohortes. Conclusiones. La incidencia durante los meses típicamente epidémicos de bronquiolitis bajó drásticamente la temporada en la que apareció el SARS-CoV-2, aumentando notablemente el año posterior, aunque sin alcanzar la incidencia previa a la pandemia. Se ha observado una incidencia alta de casos de bronquiolitis entre abril y octubre de 2021 (AU)

Introduction. A decrease has been observed during the 2020-2021 season in the incidence of hospitalizations for bronchiolitis. Changes in the evolution of the SARS-CoV-2 pandemic and in the application of preventive measures could be related to an increase in the incidence of severe bronchiolitis during the 2021-2022 season. Objective. To determine the incidence of bronchiolitis hospitalizations in a tertiary hospital during the 2021-2022 season and to compare it with previous seasons. Method. An observational, descriptive and ambispective epidemiological study. A tertiary hospital database was used to compare the incidence, etiology, and severity indicators of bronchiolitis hospitalizations. 3 cohorts were analyzed in epidemic times: the 2020-2021 season and the 2021-2022 season (prospective); and the 2018-2019 season (retrospective). A prospective cohort between the months of April and October 2021 was also analyzed. Results. The cumulative incidence of hospitalizations was 113.6/10,000 children under 2 years of age in the pre-covid season; 3.6/10,000 in the 2020-2021 season; and 65.7/10,000 in the 2021-2022 season. The percentage of admissions in PICU was 36.6%, 0% and 30.8%, respectively. The cumulative incidence of hospitalizations in the non-epidemic period was 60.8/10,000, with 19% requiring admission to the PICU. The most frequent microorganism was the respiratory syncytial virus in all cohorts. Conclusions. The incidence during the typically epidemic months of bronchiolitis drastically decreased the season in which SARS-CoV-2 appeared, noticeably increasing the next year, although without reaching the pre-pandemic incidence. A high incidence of bronchiolitis cases was observed between April and October 2021 (AU)

Malformaciones ano-rectales: cambios en el manejo neonatal en los últimos 22 años / Anorectal malformations: changes in neonatal management in the last 22 years

Introducción y objetivos. Una inspección perineal alterada o el retraso en la expulsión meconial debe hacernos sospechar una malformación anorrectal. El objetivo de este estudio es conocer la incidencia de estas malformaciones, así como el estudio de las características obstétricas y neonatales, diagnósticas y terapéuticas de estos pacientes, y sus complicaciones en los últimos 22 años. Material y método. Estudio descriptivo y retrospectivo incluyendo pacientes con diagnóstico en periodo neonatal de malformaciones anorrectales, excluyendo enfermedad de Hirschsprung, entre 2000-2021. Se establecieron dos periodos temporales para ver posibles cambios (2000-2010 versus 2011-2021). Resultados. 27 pacientes, 92,6% varones. Incidencia de 1 caso por cada 5.895 recién nacidos en nuestra región. El 88,9% fueron intervenidos con una mediana de edad de 2 días, precisando ingreso todos ellos durante una mediana de 15 días. El 95,8% recibió antibioterapia (mediana de 6 días), siendo la pauta más utilizada la asociación ampicilina, gentamicina y clindamicina; el 25% precisó ventilación mecánica invasiva (mediana de 1 día) y el 25% sedoanalgesia, tras la intervención; y 17 pacientes precisaron nutrición parenteral (media de 7,6 días). El 16,7% presentó complicaciones a corto plazo (75% infecciosas). A mediolargo plazo, el 37,5% precisó reintervención. No hemos encontrado diferencias significativas en las características clínicas ni diagnósticas entre los dos periodos temporales analizados. Conclusiones. Las malformaciones anorrectales son una causa relativamente frecuente de obstrucción intestinal en periodo neonatal que requiere un tratamiento multidisciplinar. En los últimos 22 años no hemos encontrado diferencias en cuanto a su incidencia ni en su manejo y resultado (AU)

Introduction and objectives. An altered perineal inspection or the delay in meconium expulsion should lead us to suspect an anorectal malformation. This study has aimed to know the incidence of these malformations and to study the obstetric and neonatal, diagnostic and therapeutic characteristics of these patients, and their complications in the last 22 years. Material and methods. A descriptive and retrospective study including patients having a diagnosis in the neonatal period of anorectal malformations, excluding Hirschsprung’s disease, between 2000-2021. Two time periods were established to see possible changes (2000-2010 versus 2011-2021). Results. 27 patients, 92.6% males, there being an incidence of one case per 5,895 newborns in our region. 88.9% underwent surgery with a median age of 2 days, admission being required for a median of 15 days. 95.8% received antibiotic therapy (median of 6 days), the regimen used most being the association of ampicillin, gentamicin and clindamycin; 25% required invasive mechanical ventilation (median of 1 day) and 25% sedated analgesia after the intervention. 17 patients required parenteral nutrition (mean 7.6 days). 16.7% had short-term complications (75% infectious). In the medium to long term, 37.5% required reoperation. We did not find any significant differences in the clinical or diagnostic characteristics between the two time periods analyzed. Conclusions. Anorectal malformations are a relatively frequent cause of intestinal obstruction in the neonatal period that requires multidisciplinary treatment. We have not found differences in terms of its incidence or in its management and outcome regarding the last 22 years (AU)

Sedoanalgesia para procedimientos en Unidad de Cuidados Intensivos Pediátricos (UCIP). Farmacología, efectos secundarios y control de calidad / Sedoanalgesia for procedures in Pediatric Intensive Care Unit (PICU). Pharmacology, side effects and quality control

OBJETIVOS: Analizar los fármacos más utilizados para sedoanalgesia en procedimientos realizados en una Unidad de Cuidados Intensivos Pediátricos (UCIP), medir su efectividad (nivel de sedación), efectos secundarios y control de calidad. MATERIAL Y MÉTODOS: Estudio prospectivo, observacional y descriptivo. Se recogieron datos epidemiológicos y clínicos, fármaco/s utilizado/s, nivel de sedación alcanzado, incidencias o efectos adversos y escalas de satisfacción, de pacientes de 0 a 18 años sometidos a procedimientos que precisaron sedoanalgesia. RESULTADOS: Se incluyeron 112 pacientes con una edad media de 8,3 años. El fármaco más utilizado fue el propofol (64,3%), seguido de la asociación de ketamina con midazolam (16,1%) y del sevofluorano (12,5%). En el 70,5% de los pacientes se alcanzó un nivel de sedación profunda, sin diferencias estadísticamente significativas entre los distintos fármacos. Se registraron efectos adversos en un 51,8% de pacientes, principalmente desaturación, con una frecuencia mayor al emplear propofol (p< 0,05). La puntuación en la satisfacción alcanzó el valor máximo en todos los padres encuestados, sin hallarse diferencias significativas en función del procedimiento, fármaco, nivel de sedación o efectos adversos. En el 80% de los profesionales la puntuación alcanzó ese mismo valor. CONCLUSIONES: El fármaco más utilizado y con mayor eficacia es el propofol, aunque se asocia más frecuentemente con efectos adversos. El nivel de sedoanalgesia fue adecuado en el momento de iniciar los procedimientos. El grado de satisfacción es óptimo en la mayor parte de los encuestados, aunque fue registrado en menos de la mitad de los procedimientos

OBJECTIVES: To analyze the drugs most used for sedoanalgesia in procedures performed in a Pediatric Intensive Care Unit (PICU), to measure their effectiveness (level of sedation achieved), the main side effects and to carry out a quality control. MATERIAL AND METHODS: Prospective, observational and descriptive study. Epidemiological and clinical data, drug (s) used, level of sedation achieved, incidences or adverse effects, and satisfaction scales were collected from patients from 0 to 18 years of age who underwent procedures that required sedation and analgesia. RESULTS: 112 patients with an average age of 8.3 years were included. The most widely used drug was propofol (64.3%), followed by the association of ketamine with midazolam (16.1%) and sevofluorane (12.5%). In 70.5% of the patients, a level of deep sedation was reached, with no statistically significant differences between the different drugs used. Adverse effects were recorded in 51.8% of patients, mainly desaturation, with a higher frequency when using propofol (p <0.05). Satisfaction score was maximal in all the parents surveyed, without finding significant differences based on the procedure, drug, level of sedation or adverse effects. In 80% of the professionals the score was also maximal. CONCLUSION: The most used and with the highest efficacy in absolute values drug was propofol, although it was more frequently associated with adverse effects. The level of sedoanalgesia was adequate at the time of initiating the procedures. The degree of satisfaction was optimal in most of the respondents, although it was registered in less than half of the procedures

[Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain]. / Analisis coste-utilidad de dos formulaciones de toxina botulinica de tipo A en el tratamiento del blefaroespasmo y la distonia cervical en España.

INTRODUCTION: Studies on focal dystonia showed that the formulations of botulinum toxin type A, incobotulinumtoxin-A (Inco-BTA) and onabotulinumtoxin-A (Ona-BTA), have equivalent efficacy and safety. AIM: To carry-out a cost-utility analysis of Inco-BTA administered on flexible intervals vs. Ona-BTA on a fixed interval, in the treatment of blepharospasm and cervical dystonia. PATIENTS AND METHODS: A probabilistic Markov model was designed to estimate costs (euros, 2017) and benefits (quality-adjusted life years, QALY), from the Spanish National Health Service perspective and on a 5-year time horizon, of treatment of blepharospasm and cervical dystonia with Inco-BTA (6-12 month flexible intervals) versus Ona-BTA (12-month fixed intervals). It is assumed that symptoms will re-emerge some time later in both options. Result was expressed as incremental cost-utility ratio (ICUR). RESULTS: Inco-BTA and Ona-BTA costs were 3,742 and 3,366 euros respectively, in blepharospasm, and 6,673 and 6,419 euros in cervical dystonia. Patients treated with Inco-BTA remained asymptomatic for 22.12, and 21.34 more weeks than those treated with Ona-BTA, leading in 3.040 and 3.012 QALY, respectively, in blepharospasm, and 3.471 and 3.401 QALY, respectively, in cervical dystonia. Differences showed statistical significance in all cases. ICUR was estimated as 13,576 and 4,158 euros/QALY in blepharospasm and cervical dystonia, respectively. CONCLUSIONS: Treatment of blepharospasm and cervical dystonia with Inco-BTA is a cost-effective therapeutic alternative in Spain, based on the flexibility of their administration.

TITLE: Analisis coste-utilidad de dos formulaciones de toxina botulinica de tipo A en el tratamiento del blefaroespasmo y la distonia cervical en España.Introduccion. Las formulaciones de toxina botulinica de tipo A, incobotulinumtoxinA (Inco-TBA) y onabotulinumtoxinA (Ona-TBA), han demostrado eficacia y seguridad similar en los estudios de distonias focales en los que se han comparado. Objetivo. Realizar un analisis coste-utilidad de Inco-TBA, administrada en intervalos flexibles, frente a Ona-TBA, administrada en intervalos fijos, en el tratamiento del blefaroespasmo y la distonia cervical. Pacientes y metodos. Un modelo de Markov probabilistico estimo, desde la perspectiva del Sistema Nacional de Salud español y en un horizonte de cinco años, el coste (euros, 2017) y el resultado (años de vida ajustados a calidad, AVAC) del tratamiento del blefaroespasmo y la distonia cervical mediante intervalos flexibles con Inco-TBA (6-20 semanas) y fijos con Ona-TBA (12 semanas). Se asume que los sintomas reapareceran despues de un tiempo en ambos. El resultado se expreso como ratio coste-utilidad incremental (RCUI). Resultados. El coste de la Inco-TBA y la Ona-TBA fue, respectivamente, de 3.742 y 3.366 euros en el blefaroespasmo y de 6.673 y 6.419 euros en la distonia cervical. Los pacientes tratados con Inco-TBA permanecieron asintomaticos 22,12 y 21,34 semanas mas que los tratados con Ona-TBA, lo que resulto 3,040 y 3,012 AVAC, respectivamente, en el blefaroespasmo, y 3,471 y 3,401 AVAC, respectivamente, en la distonia cervical. En todos los casos, las diferencias presentaron significacion estadistica. La RCUI fue de 13.576 y 4.158 euros/AVAC, respectivamente. Conclusiones. El tratamiento del blefaroespasmo y la distonia cervical con Inco-TBA, administrada siguiendo un esquema posologico de intervalos flexibles, constituye una alternativa terapeutica eficiente en España.

Estudio multicéntrico de costes de 2 técnicas quirúrgicas: láser GreenLight XPS 180 W vs resección transuretral de la próstata / Multicenter Study on Costs Associated With Two Surgical Procedures: GreenLight XPS 180 W Versus the Gold Standard Transurethral Resection of the Prostate

Objetivo: Analizar los costes asociados al tratamiento quirúrgico de la sintomatología del tracto urinario inferior secundaria a hiperplasia benigna de próstata mediante el láser GreenLigh XPS 180 W respecto a la técnica quirúrgica endoscópica de referencia, resección transuretral de la próstata. Métodos: Se realizó un estudio retrospectivo y multicéntrico de costes desde la perspectiva del Sistema Nacional de Salud y en un horizonte temporal de 3 meses, desagregándolos en fases temporales: prequirúrgica, quirúrgica y posquirúrgica. Los datos fueron extraídos de las historias de los pacientes intervenidos secuencialmente, con IPSS = 15, Qmax = 15 ml/seg y volumen prostático de 40-80 ml, incorporando solo costes sanitarios directos (euros de 2013) asociados a la intervención y al manejo de complicaciones. Resultados: Entre julio y octubre de 2012 se intervinieron de forma secuencial 39 pacientes con láser GL XPS y 40 con RTUP. El resultado clínico fue equivalente (94,9 y 92,5%, respectivamente) no mostrando diferencias estadísticamente significativas (p = 0,67). El coste medio total por paciente se redujo en 121 Euros en el grupo láser GL XPS respecto de RTUP; en la fase quirúrgica el coste fue superior con láser GL XPS (diferencia: 1.209 Euros; p < 0,001) mientras que fue inferior en la fase posquirúrgica (diferencia: -1.351 Euros, p < 0,001). Conclusiones: La intervención de los pacientes con STUI secundario a HBP mediante la nueva tecnología láser GL XPS se asocia a una reducción de costes respecto de la RTUP, debida a una menor duración de la estancia hospitalaria, la cual compensa el coste imputado a dicha tecnología

Objective: To analyze the costs associated with two surgical procedures for lower urinary tract symptoms secondary to benign prostatic hyperplasia: GreenLight XPS 180 W versus the gold standard transurethral resection of the prostate. Methods: A multicenter, retrospective cost study was carried out from the National Health Service perspective, over a 3-month time period. Costs were broken down into pre-surgical, surgical and post-surgical phases. Data were extracted from records of patients operated sequentially, with IPSS = 15, Qmax = 15 mL/seg and a prostate volume of 40–80 mL, adding only direct healthcare costs (Euros, 2013) associated with the procedure and management of complications. Results: A total of 79 patients sequentially underwent GL XPS (n: 39) or TURP (n: 40) between July and October 2013. Clinical outcomes were similar (94.9% and 92.5%, GL XPS and TURP, respectively) without significant differences (p = 0.67). The average direct cost per patient was reduced by 114Euros in GL XPS versus TURP patients; the cost was higher in the surgical phase with GL XPS (difference: 1209Euros; p < 0.001) but was lower in the post-surgical phase (difference: Euros − 1351; p < 0.001). Conclusions: The GreenLight XPS 180-W laser system is associated with a reduction in costs with respect to transurethral resection of prostate in the surgical treatment of LUTS secondary to PBH. This reduction is due to a shorter inpatient length of stay that offsets the cost of the new technology

Análisis coste efectividad a 2 años del tratamiento quirúrgico de la hiperplasia benigna de próstata mediante vaporización fotoselectiva de la próstata con GreenLight-PhotoVaporization 120 W versus resección transuretral de la próstata / Cost-effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-Photo vaporization 120 W versus transurethral resection of the prostate

Introducción: El gold standard del tratamiento quirúrgico de la sintomatología del tracto urinario inferior asociado a la hiperplasia benigna de próstata ha sido la resección transuretral de la próstata; GreenLight-PhotoVaporization ha demostrado ser una alternativa quirúrgica tan efectiva como aquella. Objetivo: Analizar la eficiencia comparada, en un horizonte temporal de 2 años, de GreenLight-PhotoVaporization 120 W respecto de la resección transuretral de la próstata en el tratamiento quirúrgico de la hiperplasia benigna de próstata desde la perspectiva del sistema de salud de España. Métodos: Se realizó un análisis de coste utilidad a partir de los resultados obtenidos retrospectivamente en 98 pacientes intervenidos secuencialmente mediante resección transuretral de la próstata (n: 50) y GreenLight-PhotoVaporization 120 W (n: 48). Se utilizó un modelo de Markov para estimar el coste (Euros, 2012) y los resultados (años de vida ajustados a calidad) tras un seguimiento de 2 años. Resultados: El coste total asociado al tratamiento con GreenLight-PhotoVaporization 120 W fue inferior (3.377 Euros; IC 95%: 3.228; 3.537) al de la resección transuretral de la próstata (3.770 Euros; IC 95%: 3.579; 3.945). El determinante del coste se presenta en la fase quirúrgica (diferencia: -450 Euros; IC 95%: -625; -158) debido a que GreenLight-PhotoVaporization 120 W no precisaba ingresar al paciente tras la cirugía. Conclusiones: El tratamiento quirúrgico de los pacientes con HBP mediante GreenLight-PhotoVaporization 120 W muestra mayor eficiencia respecto de la resección transuretral de la próstata al observarse una efectividad similar y un coste inferior (-393 Euros; IC 95%: -625; -158)

Introduction: Transurethral resection of the prostate is the gold standard of surgical treatment of lower urinary tract symptoms associated to benign prostate hyperplasia. The new Green Light Photovaporization has been shown to be an alternative that is as effective for this condition as the transurethral resection of the prostate. Objectives: To compare the efficiency of Green Light Photovaporization 120 W versus transurethral resection of the prostate in the treatment of benign prostate hyperplasia (BPH) in a 2-year time horizon from the perspective of the Spanish health service perspective. Methods: A cost utility analysis was performed retrospectively with the data from 98 patients treated sequentially with transurethral resection of the prostate (n: 50) and Green Light Photovaporization 120 W (n: 48). A Markov model was designed to estimate the cost (2012 Euro) and results (quality adjusted life years) in a 2-year time horizon. Results: The total cost associated to Green Light Photovaporization 120 W treatment was less (3,377 Euros; 95% CI: 3,228; 3,537) than that of the transurethral resection of the prostate (3,770 Euros; 95% CI: 3,579; 3,945). The determining factor of the cost was the surgical phase (difference: −450 Euros; 95% CI: −625; −158) because admission to hospital after surgery was not necessary with the GreenLight-PhotoVaporization. Conclusions: Surgical treatment of BPH patients with GreenLight-PhotoVaporization 120 W is more efficient than transurethral resection of the prostate in the surgical treatment of benign prostate hyperplasia as it has similar effectiveness and lower cost (-393 Euro; 95% CI: -625; -158)

Multicenter study on costs associated with two surgical procedures: GreenLight XPS 180 W versus the gold standard transurethral resection of the prostate.

OBJECTIVE: To analyze the costs associated with two surgical procedures for lower urinary tract symptoms secondary to benign prostatic hyperplasia: GreenLight XPS 180¦W versus the gold standard transurethral resection of the prostate. METHODS: A multicenter, retrospective cost study was carried out from the National Health Service perspective, over a 3-month time period. Costs were broken down into pre-surgical, surgical and post-surgical phases. Data were extracted from records of patients operated sequentially, with IPSS=15, Qmax=15 mL/seg and a prostate volume of 40-80mL, adding only direct healthcare costs (€, 2013) associated with the procedure and management of complications. RESULTS: A total of 79 patients sequentially underwent GL XPS (n: 39) or TURP (n: 40) between July and October, 2013. Clinical outcomes were similar (94.9% and 92.5%, GL XPS and TURP, respectively) without significant differences (P=.67). The average direct cost per patient was reduced by €114 in GL XPS versus TURP patients; the cost was higher in the surgical phase with GL XPS (difference: €1,209; P<.001) but was lower in the post-surgical phase (difference: €-1,351; P<.001). CONCLUSIONS: The GreenLight XPS 180-W laser system is associated with a reduction in costs with respect to transurethral resection of prostate in the surgical treatment of LUTS secondary to PBH. This reduction is due to a shorter inpatient length of stay that offsets the cost of the new technology.

Cost-effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-Photo vaporization 120 W versus transurethral resection of the prostate.

INTRODUCTION: Transurethral resection of the prostate is the gold standard of surgical treatment of lower urinary tract symptoms associated to benign prostate hyperplasia. The new Green Light Photovaporization has been shown to be an alternative that is as effective for this condition as the transurethral resection of the prostate. OBJECTIVES: To compare the efficiency of Green Light Photovaporization 120 W versus transurethral resection of the prostate in the treatment of benign prostate hyperplasia (BPH) in a 2-year time horizon from the perspective of the Spanish health service perspective. METHODS: A cost utility analysis was performed retrospectively with the data from 98 patients treated sequentially with transurethral resection of the prostate (n: 50) and Green Light Photovaporization 120 W (n: 48). A Markov model was designed to estimate the cost (2012€) and results (quality adjusted life years) in a 2-year time horizon. RESULTS: The total cost associated to Green Light Photovaporization 120 W treatment was less (3,377€; 95% CI: 3,228; 3,537) than that of the transurethral resection of the prostate (3,770€; 95% CI: 3,579; 3,945). The determining factor of the cost was the surgical phase (difference: -450€; 95% CI: -625; -158) because admission to hospital after surgery was not necessary with the GreenLight-PhotoVaporization. CONCLUSIONS: Surgical treatment of BPH patients with GreenLight-PhotoVaporization 120 W is more efficient than transurethral resection of the prostate in the surgical treatment of benign prostate hyperplasia as it has similar effectiveness and lower cost (-393€; 95% CI: -625; -158).

Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010

Economic evaluation of pharmacological cancer treatment is a critical clinical problem currently under consideration worldwide. We have analysed their main characteristics in Spain between 1990 and 2010 following a systematic review of the 29 complete economic analyses published. The pathology most frequently evaluated was non-small cell lung cancer (31 %). Cost-effectiveness analyses (69 %) were the most frequent analyses. A wide range of incremental cost-effectiveness values (295-160,667 € /QALY) has been reported, and mostly are developed from the perspective of the National Health System (65.5 %). However, none of the studies estimated the indirect costs. The major conclusion is that the absence of regulations concerning the application of the efficiency criterion in decision-making on the subject of price and financing and, most importantly, the fact that these are not included in Spanish hospitals forms make it difficult to analyse the real impact of economic evaluations of cancer treatments on such decisions

Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.

INTRODUCTION: The direct transfer of the results of pharmaco-economic studies between countries may not be suitable if the proper adaptations are not made to take into account differences in treatment patterns, resource use and costs from country to country. OBJECTIVE: To estimate the cost in Spain of treating anaemia secondary to chronic renal failure with darbepoetin alpha or epoetin alpha from a review and analysis of available current information. In addition, the role of the route of administration as a main driver of the cost will be analysed. METHOD: population: patients with chronic kidney failure induced anaemia. DATA: Medline and Embase search of studies directly comparing erythropoiesis stimulating agents. ANALYSIS: Cost minimization analysis from the perspective of a hospital pharmacy department. The main outcome chosen was the difference between the average cost per patient undergoing a 30-day treatment with epoetin alpha versus darbepoetin alpha. RESULTS: (a) haemodialysis: changing from epoetin alpha to darbepoetin alpha is associated with a cost reduction of 8.67%; CI 95%, -1.34 to 17.92 (euro 17.48; CI 95%, -2.70 to 36.13); probabilistic analysis showed that the use of darbepoetin alpha could be associated with a cost-saving probability of 94.9%. The IV administration yielded a decrease in costs of about 16.00%; CI 95%, -2.38 to 36.77 (euro 41.78, CI 95%: -6.21 to 96.04). (b) Pre-dialysis: darbepoetin alpha is associated with a cost reduction of about 11-32%. CONCLUSIONS: The use of darbepoetin alpha for the treatment of chronic renal failure induced anaemia (haemodialysis and pre-dialysis) shows higher cost efficiency than epoetin alpha in Spain; these differences increase with IV administration.

Análisis probabilístico de minimización de costes de darbepoetin alfa frente a epoetina alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica. Valoración en la práctica clínica española / Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice

Introducción: La transferencia directa de los resultados de estudios farmacoeconómicos de un país a otro no es adecuada si no se procede previamente a una adaptación de los datos a cada territorio, debido a la diversidad de utilización de recursos así como a las diferencias de costes entre países. Objetivo: Estimar el coste en España del tratamiento de la anemia secundaria a insuficiencia renal crónica con epoetina alfa o darbepoetin alfa, a partir de una revisión y un análisis de la información actualmente disponible. Además, se analiza el papel de la vía de administración como factor modulador del coste del tratamiento. Método: Población: pacientes con anemia secundaria a insuficiencia renal crónica. Extracción de datos: búsqueda en Medline y Embase de estudios de comparación directa de los agentes estimulantes de eritropoyesis. Tipo de análisis: análisis probabilístico de minimización de costes. Perspectiva: servicio de farmacia del hospital (costes farmacológicos). Variable principal: diferencia del coste medio por paciente del tratamiento de 30 días con epoetina alfa respecto de darbepoetin alfa. Resultados: a) Hemodiálisis: la sustitución de epoetina alfa por darbepoetin alfa se asocia a una reducción mensual de costes del 8,67 %; intervalo de confianza (IC) del 95 %, -1,34 a 17,92 (17,48 €; IC del 95 %, -1,38 a 36,13); el análisis probabilístico mostró una probabilidad del 94,9 % de que la utilización de darbepoetin alfa estuviera asociada a una reducción del (..) (AU)

Introduction: The direct transfer of the results of pharmaco-economic studies between countries may not be suitable if the proper adaptations are not made to take into account differences in treatment patterns, resource use and costs from country to country. Objective: To estimate the cost in Spain of treating anaemia secondary to chronic renal failure with darbepoetin alpha or epoetin alpha from a review and analysis of available current information. In addition, the role of the route of administration as a main driver of the cost will be analysed. Method: Population: patients with chronic kidney failure induced anaemia. Data: Medline and Embase search of studies directly comparing erythropoiesis stimulating agents. Analysis: Cost minimization analysis from the perspective of a hospital pharmacy department. The main outcome chosen was the difference between the average cost per patient undergoing a 30-day treatment with epoetin alpha versus darbepoetin alpha. Results: a) haemodialysis: changing from epoetin alpha to darbepoetin alpha is associated with a cost reduction of 8.67 %; CI 95 %, —1.34 to 17.92 (€ 17.48; CI 95 %, —2.70 to 36.13); probabilistic analysis showed that the use of darbepoetin alpha could be associated with a cost-saving probability of 94.9 %. The IV administration yielded a decrease in costs of about 16.00 %; CI 95 %, —2.38 to 36.77 (€ 41.78, CI 95 %: —6.21 to 96.04). b) Pre-dialysis: darbepoetin alpha is associated with a cost reduction of about 11-32 %.Conclusions: The use of darbepoetin alpha for the treatment of chronic renal failure induced anaemia (haemodialysis and pre-dialysis) shows higher cost efficiency than epoetin alpha in Spain; these differences increase with IV administration (AU)

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.

The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the BCR-ABL fusion protein, has represented a critical advance in chronic myeloid leukemia (CML) treatment. However, a subset of patients initially fails to respond to this treatment. Use of complementary DNA (cDNA) microarray expression profiling allows the identification of genes whose expression is associated with imatinib resistance. Thirty-two CML bone marrow samples, collected before imatinib treatment, were hybridized to a cDNA microarray containing 6500 cancer genes, and analyzed using bootstrap statistics. Patients refractory to interferon-alpha treatment were evaluated for cytogenetic and molecular responses for a minimum of 12 months. A set of 46 genes was differentially expressed in imatinib responders and non-responders. This set includes genes involved in cell adhesion (TNC and SCAM-1), drug metabolism (cyclooxygenase 1), protein tyrosine kinases and phosphatases (BTK and PTPN22). A six-gene prediction model was constructed, which was capable of distinguishing cytogenetic response with an accuracy of 80%. This study identifies a set of genes that may be involved in primary resistance to imatinib, suggesting BCR-ABL-independent mechanisms.

Multiplied functions unify shapes of ganglion-cell receptive fields in retina of turtle.

Retinal ganglion cells in the turtle were extracellularly recorded to define the shapes of their receptive fields by small moving light spots. To better define the geometries, spectral-light adaptations and vitreal injections of 2-amino-4-phosphonobutyric acid (APB) were used to disrupt balances in field organization along dimensions of wavelength, ON and OFF responses, and center/surround areas. Three-dimensional data plots were fit by Gaussian, Gabor, and cardioid functions to show that the shapes of receptive fields are predicted by combinations of these multiplied functions. Results indicate that Gaussian functions describe simple symmetrical receptive fields that are center-only; Gabor functions describe center/surround color-opponent receptive fields that have a ring of spike activity in the periphery; and directionally selective receptive fields, in contrast, which are asymmetrical, are described by cardioid functions adjoined to Gaussian or Gabor functions. The advantage of linking multiplied functions is that receptive fields are unified by a model that predicts progressively more complex field geometries derived from particular stimulating conditions.

Balanced interactions in ganglion-cell receptive fields.

Receptive fields of retinal ganglion cells in turtle have excitatory and inhibitory components that are balanced along the dimensions of wavelength, functional ON and OFF responses, and spatial assignments of center and surround. These components were analyzed by spectral light adaptations and by the glutamate agonist, 2-amino-4-phosphonobutyric acid (APB). Extracellular recordings to stationary and moving spots of light were used to map changes in receptive fields. ON spike counts minus OFF spike counts, derived from flashed stationary light spots, quantified functional shifts by calculating normalized mean response modulations. The data show that receptive fields are not static, but rather are dynamic arrangements which depend on linked, antagonistic balances among the three dimensions of wavelength, ON and OFF response functions, and center/surround areas.

[Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases]. / Tratamiento de la recidiva leucémica post-trasplante alogénico de medula ósea con infusión de leucocitos del donante: a propósito de 11 casos.

PURPOSE: Donor leukocyte infusions (DLI) are useful for treating leukaemic relapse after allogeneic bone marrow transplantation (BMT). We reviewed our experience with eleven patients who received DLI between 1995 and 1997. PATIENTS AND METHODS: The diagnoses prior to DLI were: chronic myeloid leukaemia (CML) in chronic phase (CP) (two patients) or accelerated phase (two patients), acute myeloid leukaemia (AML) (two patients), acute lymphoid leukaemia (ALL) (two patients), and refractory anaemia with excess blasts under transformation (tRAEB) (three patients). The patients received a median of 1.72 x 10(8) CD3+ cells/Kg (range: 0.58 x 10(8) CD3+ cells/Kg). Four patients were infused cryopreserved cells. Six patients received interferon alpha (IFN alpha) concomitantly. RESULTS: Seven patients (four CML, one AML, one ALL, one tRAEB) obtained complete remission (CR). Graft-versus-host disease (GVHD) was observed in all patients with CR and one without response. Marrow hypoplasia or severe bicytopenia occurred in four patients. Of all patients achieving CR, two died after relapsing within 3 months of DLI, while three others died of GVHD. Four patients had no response to DLI or were not evauable. Only two patients--both with CML--are alive 1096 and 374 days after DLI, the former in clinical, cytogenetic and molecular CR, and the latter in second CP after 2 months in CR. CONCLUSIONS: DLI results in CR in most patients with relapsing leukaemia or myelodysplasia after BMT, especially in CML patients. The anti-leukaemia effect is highly correlated with GVHD. This complication and marrow hypoplasia remain major causes of morbidity and mortality of this procedure.

[ENCAPSULATED CORD METHOD(Enterotest) COMPARED WITH FECALTEST ON THE DIAGNOSIS OF CRIPTOSPORIUM Sp E ISOSPORA belli In HIV(+)Patients with Gastrointestinal Symptoms] / Método de la Cuerda Encapsulada(Enterotest)comparado con el examen de heces en el diagnóstico de Criptosporidiumspp. e Isospora belli en pacientes VIH(+) con síntomas gastrointestinales.

Fecal samples and small intestinal content obtained by Enterotest were submitted between December 1994 and January 1996, by HIV (+) patients with gastrointestinal symptoms.Unconcentrated and concentrated fecal samples (by Sheater, Ritchie and Spontaneous Sedimentation) and intestinal content obtained by Enterotest, all stained by modificated Ziehl-Nielsen method, were compared (multiatributive comparison) based on the following parameters: yield, each test cost, morphology and the number of parasites per slide, in order to diagnose Cryptosporidium spp. e Isospora belli.Intestinal content obtained by Enterotest on the diagnosis of Cryptosporidium spp. e Isospora belli was not better than the fecal samples but it is more expensive. However, it reached a good diagnostic yield with adequate morphology, and a number of parasites per slide. Furthermore, it can be used as a second line diagnostic method (first line = fecal samples) and as an alternative in places where the use of endoscopy is not available.

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

The best method for peripheral blood progenitor cell (PBPC) mobilization in patients with multiple myeloma (MM) remains controversial. We report the results of two different methods of PBPC collection for autologous transplantation in 40 patients with stage II or III MM. In group I (n = 18), HD-CY, 4 g/m2 i.v., was administered followed by GM-CSF, 8 microg/kg/day s.c., until the end of collection, starting the leukaphereses after hematological recovery (>1 x 10(9)/l WBC). In group II (n = 22), G-CSF, 10 microg/kg/day s.c., was used alone until the last day of collection, starting consecutive aphereses on the 5th day. A minimum of two aphereses were performed to collect at least 2 x 10(6)/kg CD34+ cells. Both patient groups were comparable for age, sex and clinical prognostic features as well as previous therapies. In group I, the median yields per pheresis were: MNC 1.47 (1.38-2.32) x 10(8)/kg, CFU-GM 0.82 (0.18-13.2) x 10(4)/kg and CD34+ cells 1.98 (0.96-6.96) x 10(6)/kg. In group II these results were: MNC 2.44 (2.06-3.6 x 10(8)/kg) (P = 0.03), CFU-GM 0.75 (0.16-7.8) x 10(4)/kg and CD34+ 1.05 (0.32-3.4) x 10(6)/kg (P = 0.02). The median number of aphereses performed in each group was 5 (4-12) with a median of 5.24 +/- 2.51 in group I and 3 (2-6) with a median of 3.1 (+/- 0.91) in group II (P = NS). Hospitalization for PBPC mobilization was required in all patients in group I and the treatment-related toxicity was greater in this group: 12 patients (66%) developed fever requiring antibiotics during the neutropenic period after HD-CY and six (33%) patients required transfusion support. After receiving busulfan 12 mg/kg p.o. and melphalan 140 mg/m2 i.v., as the conditioning regimen, the median periods to reach granulocytes (>0.5 x 10(9)/l) and platelet (>20 x 10(9)/l) engraftment were 12 and 11 days respectively (ranges 8-20 and 10-16) in group I (HD-CY plus GM-CSF group), and 11 and 13 days respectively (ranges 7-42 and 10-38) in group II (G-CSF group) (P = NS). In conclusion, these data suggest that although HD-CY plus GM-CSF is superior to G-CSF alone based on mean CD34+ cell yield per pheresis, adequate CD34+ cell collections can be achieved with G-CSF alone in most MM patients with less toxicity and with simplification of the procedure.